Market Intelligence, Clinical Progress, and High-Purity Reagents for Solid Tumor and Immuno-Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ALCAM/CD166 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ALCAM/CD166 ECD-Fc Fusion Protein High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. HEK293 expressed for native glycosylation. |
View ALCAM/CD166 Products |
| Gene Delivery | ALCAM/CD166 Premade Lentivirus Full-length ORF for stable cell line construction. Ideal for internalization assay development. |
View ALCAM/CD166 Products |
| Benchmark Ab | Anti-ALCAM/CD166 (Sequence of Praluzatamab / OBT076) Recombinant positive control antibody for ADC and bispecific benchmarking. |
View ALCAM/CD166 Products |
| Validator | ALCAM/CD166 siRNA Set For knockdown verification and specificity controls in binding assays. |
View ALCAM/CD166 Products |
| Related Target A | CD6 Direct ligand of ALCAM; critical for T-cell adhesion and co-stimulation. |
View CD6 Products |
| Related Target B | EpCAM Synergistic cancer stem cell marker; co-targeting strategy validation. |
View EpCAM Products |
| Related Target C | CD44 Parallel adhesion molecule in tumor metastasis; synergistic targeting potential. |
View CD44 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Internalization Efficiency (ADC Development) | High-purity ECD-Fc (>95%) with intact glycosylation sites; Lentivirus system for stable cell lines expressing full-length ALCAM at physiological levels. |
| Cross-species Cyno/Mouse Evaluation | Human/Mouse/Cyno ALCAM ECD-Fc ortholog proteins available with >95% purity; Sequence verified by mass spectrometry for epitope conservation analysis. |
| Tumor Microenvironment (TME) Specificity | Native Glycosylation from HEK293 ensures precise structural fidelity for protease-cleavage or pH-dependent binding assays. |
| CD6 Ligand Competition / Selectivity | Homolog panel including CD6 and IgSF family proteins strictly verified by mass spec for off-target binding assessment. |
| Subfamily / Off-target Selectivity | Homolog panel proteins (CD6, CD44) with Sequence Verified identity for counter-screening. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included for assay calibration. |
| False Positives / Specificity Controls | Validated siRNA included for target-specificity confirmation in cell-based assays. |
Live ALCAM/CD166 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for ALCAM/CD166 therapeutics is intensifying, with major players shifting focus from traditional mAbs to Antibody-Drug Conjugates (ADCs) and conditionally active biologics. Notable programs include CytomX Therapeutics' Probody ADC CX-2009 (Praluzatamab ravtansine) in HR+/HER2- and triple-negative breast cancer, and Oxford BioTherapeutics' OBT076 (Phase I/II) targeting ovarian, pancreatic, and gastric cancers. Because ALCAM is broadly expressed on some healthy epithelia, classical targeting can lead to on-target, off-tumor toxicity. As first-generation masked therapies (e.g., Probodies) evaluate clinical efficacy, the next wave of R&D is targeting advanced TME-conditional release, bispecific formats, and combination strategies with immune checkpoint inhibitors to widen the therapeutic window.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADC (incl. Probody) | CytomX Therapeutics, Oxford BioTherapeutics, Genentech | Breast, NSCLC, Ovarian, Pancreatic, Gastric | Internalization Assay (Need high-purity ECD-Fc and stable cell lines) |
| Bispecific Antibody | Various Preclinical | Refractory Solid Tumors, Immuno-Oncology | Heterodimer Validation (Need Cross-reactive Abs and CD6 competition assays) |
| CAR-T | Academic Institutions, Early Biotech | Solid Tumors | Cell Surface Density Validation (Need Lentivirus for stable expression) |
| Monoclonal Antibody | Preclinical pipelines | Colorectal Cancer | Selectivity Assay (Need Human vs Ortholog Proteins) |
Assay Strategy & Molecular Differentiation
To achieve best-in-class targeting of ALCAM/CD166, antibody developers must consider:
- Internalization Rate: Rapid internalization (<30 min detectable) is critical for ADC payload delivery. Use full-length ALCAM stable cell lines (Lentivirus) for quantitative flow cytometry and confocal microscopy assays.
- pH-Dependent Binding: Screening for pH-dependent affinity (strong binding at pH 6.0, weak at pH 7.4) can improve tumor selectivity and reduce on-target off-tumor toxicity.
- Epitope Specificity: Non-blocking epitopes preserve CD6 binding (lower immune toxicity), while blocking epitopes may be desired for immunomodulation. Use high-purity CD6 protein for competition assays.
- Cross-Species Translation: Human, Mouse, and Cyno ortholog proteins (>95% purity, sequence verified) enable robust preclinical tox and efficacy studies.
TarMart provides the full reagent ecosystem to address these challenges: ECD-Fc antigens with native glycosylation, lentiviral constructs for stable cell lines, benchmark antibodies (sequence-verified), and orthogonal controls (siRNA, homolog panels).